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ABSTRACT 
Background:  
Mass drug administration (MDA) treatment of active trachoma with antibiotic is 
recommended in any district where the prevalence of trachoma inflammation, follicular (TF) 
is ≥10% in children aged 1-9 years. MDA then continues for at least three annual rounds 
before resurvey. In The Gambia the PRET study found that discontinuing MDA based testing 
a sample of children for ocular Chlamydia trachomatis(Ct) infection after one MDA round 
had similar effects to continuing MDA for three rounds.  We compared the costs of 
examining and testing a sample of children for Ct with those of annual MDA rounds.   
 
Methods:  
The implementation unit in PRET The Gambia was a census enumeration area (EA) of 600-
800 people. Personnel, fuel, equipment, consumables, data entry and supervision costs were 
collected for census and treatment of a sample of EAs and for the examination, sampling and 
testing for Ct infection of 100 individuals within them. Programme costs and resource 
savings from testing and treatment strategies were inferred across all 102 EAs in the study 
area, and compared.   
 
Results: 
Census costs were $103.24 per EA plus initial costs of $108.79. MDA with donated 
azithromycin cost $227.23 per EA. The mean cost of examining and testing 100 children was 
$796.90 per EA, with Ct testing kits costing $4.80 per result. A strategy of testing each EA 
for infection is more expensive than two annual rounds of MDA unless the kit cost is less 
than $1.38 per result. However stopping or deciding not to initiate treatment in the study area 
based on testing a sample of EAs for Ct infection creates savings relative to further 
unnecessary treatments, even at current test pricing. 
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Conclusion: 
 Resources can be saved by using tests for chlamydial infection to determine that initial or 
subsequent rounds of MDA for trachoma are unnecessary.  
 
 AUTHOR SUMMARY 
 
Trachoma, caused by infection with a bacterium (chlamydia) is controlled by mass drug 
administration (MDA), which is recommended yearly for districts in which a trachoma 
problem has been found to exist. The decision, after several rounds,  that MDA is no longer 
needed is currently based on clinical signs of trachoma, but these are an unreliable indicator 
of infection. The PRET study, in the Gambia, found that tests for infection could be used to 
show that subsequent rounds of MDA were redundant. This paper shows, by estimating the 
costs, that testing children in a sample of census districts for infection can save resources 
compared to (unnecessary) rounds of MDA.   
 
 
INTRODUCTION 
Trachoma, caused by ocular infection with Chlamydia trachomatis (Ct), is the leading 
infectious cause of blindness worldwide and is estimated to cause 3.6% of the world’s 
blindness [1]. The presence of follicles and inflammation in the upper tarsal conjunctiva, 
known as active trachoma, is characteristic of childhood infection. Following years of 
repeated infection, the upper tarsal conjunctiva may become so severely scarred that the 
eyelashes turn inwards, rub on the eyeball and cause corneal opacity and blindness. 
 
The World Health Organization (WHO) estimates that worldwide, 40.6 million people have 
active trachoma, 8.2 million people have in turned eyelashes (trichiasis), and 1.3 million are 
blind as a result of trachoma [1,2]. It was estimated in 1995 that $2.9 billion is lost in annual 
revenue as a result of the loss of vision arising from trachoma [3]. Trachoma is most 
prevalent in poor, rural communities with low standards of hygiene and sanitation. It is 
thought to be endemic in 57 countries [2].  
 
The WHO recommendations for the control and elimination of trachoma are based on a 
strategy with the acronym “SAFE”: Surgery for in turned eyelashes, Antibiotics to treat 
ocular Ct infection, Facial cleanliness and Environmental improvement to reduce 
transmission of the infection. The WHO recommends that mass treatment with an antibiotic 
such as azithromycin should be given annually to districts or communities where the 
prevalence of follicular trachoma (TF) is ≥10% in children aged 1-9 years, continuing for at 
least three rounds before the need to re-survey. In some settings however, including the 
Jareng village cluster in The Gambia [4] and Rombo district in Tanzania [5], a single round 
of high coverage mass azithromycin reduced Ct infection to very low and unsustainable 
levels, although the prevalence of TF would still have indicated that intervention was needed. 
Testing for Ct demonstrated that further treatments were unnecessary.   
 
In 2007, The Gambia implemented a national plan for trachoma control [6] with a donation of 
azithromycin through the International Trachoma Initiative. In this plan, based on a 2006 
survey [7], extrapolation and local knowledge, 11 out of 37 districts were assigned to mass 
drug administration (MDA) with azithromycin. The Partnership for the Rapid Elimination of 
Trachoma (PRET) study [8] aimed, inter alia, to test whether one round of MDA would be 
sufficient to control active trachoma across a wide geographical area, comprising four of the 
eleven districts assigned to MDA and containing 67,000 people. The study compared 
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communities randomised to receive yearly MDA for three years or to a stopping rule (SR) in 
which mass treatment would cease if the estimated prevalence of either TF or Ct infection at 
six months were sufficiently low. A further stopping rule was applied at the district level, 
according to which  treatment in  non-study communities would also cease if the district 
prevalence of  infection or of TF were sufficiently low,. In the study, the TF prevalence in 0-5 
year-olds in the study area was reduced below 3% after one round of treatment and Ct 
infection, which was at a low level initially, was not detectable in any child at 12 and 18 
months of follow up. The study found no difference in outcome (TF or Ct infection at 36 
months) between the stopping rule communities and those in which treatment continued [9], 
illustrating that tests for Ct infection (or clinical examination for TF) could be used to 
demonstrate that initial or subsequent rounds of MDA were redundant.  
 
Data were gathered during PRET The Gambia with the aim of comparing the programme 
costs of implementing a stopping rule based on tests for infection with those of further rounds 
of treatment and to explore the situations in which testing for infection would have a cost 
advantage over two further treatments. We report on these cost data and on their application 
to this and other possible testing and treating strategies.   
 
METHODS: 
PRET Study: 
The study was conducted in the Foni Bintang and Foni Kansala districts in Western Region, 
and in Central Baddibu and Lower Baddibu in North Bank Region. For census purposes, The 
Gambia is divided into geographically defined census Enumeration Areas (EAs), of similar 
population size, notionally containing 600-800 people. An EA is a useful unit for 
representative sampling, as randomly choosing EAs is equivalent to sampling settlements 
with probability proportional to their size. EA geography varies in ways which might 
influence costs; an EA is either a segment of a large settlement (segment) a single medium-
sized settlement (single), or made up of multiple adjacent small settlements (multiple).  
 
Randomisation: 
The randomisation scheme in PRET has been described previously [10]. Briefly, all 102 EAs 
were randomly assigned to one of four arms: 1) standard treatment coverage, SR; 2) standard 
treatment coverage, 3 annual MDAs; 3) enhanced treatment coverage, SR; 4) enhanced 
treatment coverage, 3 annual MDAs; under the restriction that each settlement was treated in 
the same way (all EAs representing segments of the same settlement were in the same arm). 
For the study, a random selection of 48 EAs for sampling was made such that 12 EAs per arm 
and per district were selected (3 EAs per arm per district) and such that each large settlement 
was represented by only one of its segment EAs. This ‘sample’ of 12 EAs per district then 
served as the basis for implementing district-level stopping rules in the non-study EAs. 
 
Field and laboratory work: 
Details of PRET in The Gambia have been described elsewhere [8,10]. Briefly, all members 
of every household in all 48 EAs were listed in a census and a random sample of 100 children 
aged 0-5 years per EA had both eyes examined for the clinical signs of trachoma using the 
WHO simplified grading system [11]. An ocular swab was then taken for detection of ocular 
Ct infection by Amplicor Polymerase Chain Reaction (PCR) (Roche Molecular Systems, 
Branchburg, NJ, USA), as previously described [12]. A new random sample of 100 children 
aged 0-5 was examined in each EA at 6, 12, 18, 24, 30 and 36 month follow-up time points. 
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Samples were processed by two laboratory technicians at Medical Research Council (MRC) 
Laboratories, The Gambia, by Amplicor PCR. The manufacturer’s instructions were 
followed, except for sample preparation where a previously published method was used [12], 
and the extracts of five swabs were pooled, with individual testing of any positive pools. 
 
MDA in PRET: 
At baseline, all 102 EAs in the four districts were mass treated with azithromycin by the 
Gambian National Eye Health Programme (NEHP). EAs assigned to standard treatment 
coverage were visited on a single day, whereas those assigned to enhanced coverage were 
visited a second day to treat those not treated on the first visit. The treatment teams were kept 
unaware, on their first visit to an EA, of the coverage assignments. Children were dosed  
using height sticks, with cut-offs optimally derived from local height/weight data to minimise 
the risk of over- and under-dosing [6,13]. EAs were usually treated by a team of six people, 
working in three pairs, plus a driver. In segment EAs, all six team members worked together 
whereas in multiple EAs pairs would work on their own in the different settlements. In each 
pair, one measured the height and distributed the treatment, while the other recorded the 
treatment information against the census in the treatment book. 
 
Stopping rule in PRET:  
Under the stopping rule, the decision to treat at 12 months post-baseline was based on the 
clinical examination and ocular Ct infection data at 6 months (Table 1).  MDA was 
discontinued in study EAs in the SR arms if there were either no cases of Ct infection or no 
cases of TF in the 100 sampled individuals (equivalent to 95% confidence that the true 
prevalence was less than 5%). Furthermore, MDA was discontinued throughout a district 
(excluding those EAs randomised to three annual treatments) if, based on the EAs that were 
sampled, there was 95% confidence that the prevalence of infection, (or of TF) in the district 
was below 5%.        
 
Cost data collection: 
 Cost data, which included personnel, fuel, equipment, consumables, data entry and 
supervision, were collected for census, sampling and examination.  Treatment cost data were 
collected 12 months post baseline from the 12 EAs assigned to the enhanced coverage 
treatment arm, with the costs for one day of treatment (standard coverage) inferred by 
removing the costs of the second day from the total EA treatment cost. Examination cost data 
were collected from these same EAs at 18 months post baseline. Efforts were made to 
identify and exclude the costs of concurrent research activity, such as personnel and 
consumables involved in taking eyelid photographs, and completing consent forms. 
 
As is recommended for cost studies [14], worksheets detailing all costs involved for the day’s 
activities(examination or treatment) were completed  each day. Unit costs were obtained from 
local sources when available, and when not, the original source price was taken. The 
laboratory cost of processing the samples   was calculated using information provided by the 
MRC Laboratories, The Gambia. Costs were obtained in US Dollars ($), British Pounds 
(GBP), and Gambian Dalasi (GMD). GMD and GBP costs were converted to $ using a 
historic currency conversion of an average of 366 days from the 1st January 2009 to the 1st 
January 2010 (http://www.oanda.com/currency/historical-rates/). For this time period, 1GMD 
= $0.0377, and 1GBP= $1.5665. Cost data were entered and analysed in Microsoft Excel 
2007. 
 
 Personnel: 
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 Salaries, including overheads, were converted to a daily rate. For the census, it was assumed 
that NEHP staff would first attend a training workshop, and that subsequently one census 
taker, using a motorcycle, could census one EA/day. For the treatment team, per diems to 
cover food and accommodation in the field were given as a single payment based on the 
expected number of days needed to complete the treatment. The team’s total per diem was 
divided by the number of days worked to obtain a daily rate. The PRET field team contained 
research workers and NEHP Community Ophthalmic nurses (CONs). For costing we 
assumed that three NEHP Community Ophthalmic Nurses (CONs) (for form filling, grading 
and the field lab) and a NEHP driver would undertake the work.. Examination team received 
per diems for each day worked. Volunteers from the communities who facilitated field work 
were also compensated for their time and effort. For the laboratory, personnel costs included 
the salaries of two lab technicians, employed locally by the MRC Laboratories, who spent 
85% of their time processing the samples. Based on an average of 920 samples being 
processed a week, a lab personnel cost per sample processed was calculated. 
 
Fuel: 
 The cost of fuel was calculated based on the distances in kilometres (km) travelled by the 
teams as read from the vehicle dashboards and the refuelling costs. 
 
Equipment: 
Equipment for the treatment team included the vehicle, height sticks and weighing scales. 
Equipment for the examination team included the vehicle, table, chairs and loupes. 
Laboratory costs were obtained for all equipment necessary to run Amplicor PCR. The 
equipment cost/day was calculated by dividing the capital cost, by the equipment’s life 
expectancy in years multiplied by 345 (number of assumed working days per year). 
 
Consumables: 
For the census, consumable costs of clipboards, pens, phone credit and stationery were 
included. For treatment, consumables included the cost of medication. Azithromycin for 
trachoma control is donated free to the NEHP and to other trachoma control programmes by 
the International Trachoma Initiative, but storage and transport costs are met by the 
programmes and were included. The costing gold standard [14] of taking into account the 
opportunity cost (i.e. when goods or services are donated, a ‘replacement’ cost is imputed) 
was applied  (drugs were assumed purchased rather than  donated). In this case we assumed 
the online market rates of $20 for 30x250mg azithromycin tablets, and $9 for a bottle of 30 
ml paediatric oral suspension. Costs of tetracycline eye ointment, which is purchased and 
offered to children aged under 6 months and pregnant women in MDA campaigns were 
included. For examination, field consumables included swabs, tubes, labels, paper, gloves, 
waste bags, ointment, torches and batteries, phone credit and stationery. For the laboratory, 
costs of all consumables necessary for processing samples by Amplicor were included, 
together with the cost of kits.   
 
Test kit costs: 
We define the Amplicor test ‘kit cost’ as the amount spent on Amplicor kits to generate one 
test result using a strategy of  testing in pools of five and retesting all positive or equivocal 
pools.  
 
Data entry: 
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We assumed the NEHP would enter data rather than using the PRET research data entry 
system. We assumed that one data entry clerk would be employed, entering two EAs per day 
for treatment data, and four EAs per day for examination data.  
 
Supervision: 
We assumed that the NEHP manager (a senior civil servant) would spend one day per week 
supervising the census, and two days per week in the field to supervise the treatment and 
examination teams (one day per team). Supervision costs included the manager’s salary, 
vehicle (car depreciation) and fuel, calculated as outlined above. For the laboratory, we 
assumed that locally employed technicians were supervised by a Scientific Officer (a scientist 
with a Master’s degree employed by the MRC on a sub-regional salary scale) at 5% of their 
time. 
 
Cost calculations: 
The treatment and exam cost data were collected from twelve EAs (five multiple, two single 
and five segments). Census costs were estimated from records of training workshops and 
field records. Total EA level costs were calculated by summing the personnel, fuel, 
equipment, consumables, data entry and supervision costs. For both examination and 
treatment, when more than one EA was visited in a day, the number of individuals treated, or 
number of children examined, in the EA was used to provide a weighted cost per EA for 
items that were not “per individual/child” (personnel, fuel, and equipment costs). Summary 
estimates were made for each type of EA and then extrapolated for the study sample (48 
EAs), and for the whole study area (102 EAs), according to their decomposition by EA type 
(Table 3). Results are expressed as total costs in US dollars ($) over the study area, costs per 
EA and costs per head of the population of the study area.   
 
Evaluation of test/treat scenarios:  
Based on the results of the PRET study, we calculated cost estimates for four alternatives to 
the base strategy of three rounds of MDA throughout the study area, as illustrated in Figure 1.   
We considered two alternatives directly examined in the study, namely 1) a decision to 
discontinue MDA in individual EAs based on testing a sample of 100 children within them 
after the first MDA round, and 2) a decision to discontinue MDA over the whole study area 
based on testing a subsample of EAs for Ct infection. Further, we examined the costs of 
decisions 3) to discontinue MDA based on demonstrating a reduction in TF below 5% after 
the first MDA round without laboratory testing and 4) to apply tests for Ct infection before 
embarking on MDA at all. Finally, we considered the effect of the cost of azithromycin in 
alternatives 1) – 4) if the programme had purchased the drug rather than receiving it from the 
donation programme.        
 
Sampling calculation: 
Following recommendations for sampling surveys in the WHO manual for trachoma 
programme managers[15] we estimated the number of EAs that would have been needed  to 
be examined and/or tested to meet the PRET stopping rules of  95% confidence that the 
prevalence of TF or of Ct infection in the study area were less than 5%. . These calculations 
were based on the design effects [16] estimated in EA summarised data from PRET at 
baseline and 6 months.[9]   
 
Ethical approval: 
The study was conducted in accordance with the declaration of Helsinki. Written informed 
consent was given by adult subjects or by the parent or guardian of child participants.  Ethical 
7 
 
approval was obtained from the London School of Hygiene & Tropical Medicine (LSHTM), 
UK, Ethics Committee and The Gambia Government/Medical Research Council (MRC) joint 
Ethics Committee, The Gambia.  
 
RESULTS:  
PRET study[9]: 
The baseline TF prevalence was 6.5% of 0-5 year olds. Six months after the baseline mass 
treatment, TF prevalence was 2.4% (95% CI 1.6-3.1) and no Ct infection was found in any of 
the 24 EAs randomised to the stopping rule. Implementing the stopping rule led to mass 
treatments being discontinued in these 24 EAs. Furthermore, implementing the district 
stopping rule led to treatment being discontinued in all 54 non-study EAs across all four 
districts. MDA only continued in the 24 EAs randomised to three annual treatments, where 
MDA at 12 months and 24 months was implemented regardless of the prevalence of TF or of 
infection. At baseline, the prevalence of Ct infection was 0.8% (95% CI 0.3-1.2). On average, 
enhancing coverage by making an extra visit improved MDA coverage of 0-9 year-olds by 
3%.[9] At 36 months there were no differences in the study outcomes between the study arms 
(Table 1). Specifically, neither enhanced coverage nor the two additional mass treatments in 
the 3x annual treatment arm had any effect on TF or infection prevalence at 36 months. There 
were also no differences at intermediate time-points. Thus, a single round of MDA reduced 
TF to low levels, and there were no apparent benefits to two further rounds of mass treatment, 
relative to discontinuing MDA post-baseline based on tests for infection[9] .   
 
Census costs: The breakdown of census costs is shown in Table 1. The cost of the census was 
$108.79 for training plus $103.24 per EA. The estimated cost of census in the study area was 
$10,639.27. Per diem costs were the greatest component of training, and supervision costs the 
greatest component of the census.  
 
Treatment costs: 
Over the study area the average cost of one MDA round in an EA was $227.73 for standard 
treatment and $296.05 for enhanced treatment (Table 3). The estimated cost of a standard 
round of MDA in the study area was   $23,228.46, or $0.35 per head of target population, 
increasing to $0.39 per head for the extra visit in the enhanced treatment. Personnel 
represented the greatest treatment cost, followed by supervision (Figure 2). Treatment costs 
varied slightly depending on the geography of the EA, with single EAs being cheapest to treat 
and segments the most expensive (data in Table 2).  
 
Examination costs: 
Over the study area the average EA cost of examining and testing 100 children was $796.90. 
As anticipated costs varied by EA geography: and were $773.90, $869.90 and $795.40 in 
multiple, single and segment EAs respectively (Table 4).  The major laboratory cost was the 
Amplicor kit cost, at $480.15 for 100 samples per EA (Figure 2). The major field costs were 
personnel and supervision (Figure 2), whose relative importance varied depending on the 
geography of the EA (data in Table 4). Examining and testing all EAs in the study area, 
adjusting for EA type, has an estimated programme cost of $81,283.80 or $ 1.21 per head. 
Examination alone, without ocular infection swab sampling or testing cost $24,869.64 over 
the study area, $243.82 per EA or $0.37 per head (data from Table 4).  
 
Sampling calculations: 
The PRET baseline EA summarised prevalence of Ct infection was 0.8% with a design effect 
of 4.0, The 6 month post-baseline EA summarised Ct prevalence was 0.1% with a design 
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effect of 1.9. For an underlying Ct infection prevalence of 0.5-1.0% with these design effects 
a sample of at most six EAs would provide 95% confidence that the infection prevalence in 
the study area was less than 5%.  Conservatively we assume below that 8 EAs would be an 
adequate sample. The 6 month post-baseline EA summarised prevalence of TF across all 
sampled EAs was 2.4% with a design effect of 4.3. For an assumed underlying TF prevalence 
of 2-3%, approximately 18 EAs would be required to be sampled to demonstrate that TF was 
less than 5% with 95% confidence. 
 
Base strategy (census plus 3 MDA rounds-outlined in red in Figure 1): 
From the data in Table 2 the estimated cost of census in the study area is $10,639.37 or $0.15 
per head. From the data in Table 3 three rounds of standard MDA cost $69,685.38 in the 102 
EAs in the study area or $1.05 per head.  The total estimated cost of the base strategy applied 
in the study area is $80,324.75 or $1.20 per head. 
 
Alternative 1 (discontinue MDA based on testing each EA-outlined in blue in Figure 1): 
From the data in Tables 2,3,and 4 the costs of census plus one standard MDA round plus 
examining and testing 100 children in each EA once is $115,151.63 or $1.71 per head. . Thus 
it costs $34,826.88, $359.50 per EA or $0.51 per head more to test 100 children per EA for 
Ct infection than to treat them annually twice. Figure 3 demonstrates how this depends on the 
kit cost –in order for testing  using an Amplicor-like test  to produce savings relative to two 
unnecessary MDA rounds, a kit cost of $1.38 or less per result would be required  
 
Alternative 2 (discontinue MDA based on testing a sample of EAs- outlined in green in 
Figure 1):  
In the PRET study, examination and testing was conducted in 48 EAs at an estimated 
programme cost of $38,163.36 (Table 4). Combining this with census and treatment costs 
across the study area from Tables 2 and 3 leads to a cost estimate of $72,004.09 or $1.07 per 
head. Implementation of the district level stopping rules across the study area based on these 
48 EAs would have resulted in a saving of $8,320.66, or $0.13 a head.  However, following 
the above sampling calculations, if a sample of 100 children in 8 EAs were examined and 
tested for Ct infection to show that two further MDA rounds were unnecessary in the study 
area, this would cost $40,242.93 or $0.60 per head and save $40,081.82 or $0.60 a head 
across the study area.   
 
Alternative 3 (discontinue MDA based on examining a sample of EAs-outlined in orange 
in Figure 1): 
Following the above sampling calculations, we assume that 100 children in each of 18 EAs 
could be examined for TF (without testing for Ct infection) to show that two further MDA 
rounds were unnecessary in the study area. From the data in Table 2, 3, and 4 this costs 
$38,256.49 or $0.57 a head, and would save $42,068.26 or $0.63 a head across the study area.      
 
Alternative 4 (do not start MDA based on tests for infection-outlined in purple in Figure 
1):  
. Based on the above sampling calculations we assume that we could demonstrate that three 
rounds of MDA were unnecessary through census, sampling and testing in eight of the 102 
EAs. From data in tables 2 and 4 this would cost $7,309.91 or $0.11 per head.  Thus, if MDA 
were not to start at all when baseline infection was less than 5% with 95% confidence, there 
would be a saving of $73,014.84, or $1.09 per head.     
 
Alternative 5- bought azithromycin  
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If azithromycin had been bought rather than donated, census followed by three rounds of 
MDA in the study area would have cost $461,723.05 or $ 6.91 per head (data in Tables 2 and 
3). Census followed by one standard round of MDA would cost $161,031.13 or $2.40 per 
head. This is roughly twice the $1.21 cost per head of testing 100 children for infection in 
every EA.  
 
DISCUSSION: 
We have shown, in the context of the findings of the PRET study, that tests for infection can 
be applied in trachoma control to prevent further redundant MDA rounds and that in 
circumstances where an initial MDA round reduces infection below the decision threshold, 
this will save  resources. Using programme costs estimated for The Gambia, discontinuing 
MDA based on testing 100 children for Ct infection in each of a sample of communities after 
one round of MDA, offers cost savings of $0.57 a head relative to continuing for three MDA 
rounds, even when the Amplicor test is used. Since PRET found no difference in 
effectiveness between these study arms, this is also a cost-effective strategy.  
 
 The 3rd WHO Global Scientific Meeting on trachoma [17] made recommendations for 
trachoma surveillance post-MDA based on the sub-district, where a sub-district is a natural or 
convenient segmentation of a district of 250,000 people. Here we present calculations 
extrapolated to the whole PRET study area of 102 census EAs and 67,000 people, which 
despite being made up of four Gambian districts, we believe best corresponds to the ‘sub-
district’ envisaged in the recommendations.            
 
We found the average EA treatment cost in The Gambia, based on a single treatment visit to 
each community not including census was $227.73, which equates to $0.35 per head of 
population. Enhancing coverage via an extra treatment visit to each community cost a further 
$0.04 per head, improved coverage in 0-9 year-olds by about 3%, but had no effect on 
outcome and, in this setting, was not worthwhile. The treatment costs are less than the $ 1.53 
per head reported in South Sudan [18], but similar to the $ 0.25 estimate from Mali [19]. A 
cost of ≤$0.50 per person for trachoma treatment has been quoted in the literature when 
assessing programme sustainability or cost savings through integrated treatment campaigns 
targeting several neglected tropical diseases [18,20,21]. Our results are in line with this 
estimate. The calculated total annual cost of mass treatment with standard coverage and 
donated azithromycin for the study area was $23,224 per round. The main drivers were 
personnel costs followed by supervision. Others have also found personnel to be the major 
cost from all cost categories in population-based prevalence surveys [22] and trachoma mass 
antibiotic treatment distributions [18]. Interestingly, both these studies found transportation to 
be the next most expensive cost category after personnel, whereas it was not a major cost in 
our study. This is likely a reflection of the high population density, small distances travelled 
and relatively good terrain in The Gambia. Costs will likely be higher in countries where the 
population is sparse and the terrain unforgiving, reflecting increased personnel and 
transportation costs. This is apparent in the study from the Ayod county of Southern Sudan 
where a plane had to be chartered to transport personnel [22].  
 
The average cost of testing 100 children per EA for Ct infection was $796.90. The major 
contribution was the kit cost of Amplicor testing at $480.15 per EA. This is less than the cost 
of 100 Amplicor tests because of the strategy of testing in pools of five and retesting 
individual samples in positive pools [23], which here reduced costs by over 60% relative to 
testing each sample individually. We show that, at the EA level, testing using an ‘Amplicor-
like’ test would not cost less than two further rounds of MDA unless the kit cost for testing 
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the EA was below $138 per EA or $1.38 per result. However because the number of EAs that 
would need to be tested to establish district level prevalence with sufficient precision to guide 
MDA treatment decisions is, in this case, relatively small, a district level decision process 
similar to our ‘stopping rule’ has the potential to save money even with the current costs of 
testing. The Amplicor test used in this study is no longer commercially available, but 
alternatives such as the COBAS Amplicor CT/NG Test, Aptima Combo 2 Assay (Gen-Probe 
Inc. CA, USA), and the Real-time CT/NG Assay (Abbott Laboratories, Illinois, USA) 
platform are no cheaper and have not had pooling strategies validated. Nevertheless, this 
study suggests that even the application of relatively costly Nucleic Acid Amplification Tests 
(NAATs) may save resources if a sample of representative communities was tested for 
infection before MDA was implemented            
 
The ‘stopping rule’ used in PRET was an arbitrary one based on the observation that if no 
infections were found in a sample of 100 children then there was 95% confidence that the 
true infection prevalence was less than 5%. Whether an infection prevalence of 5% in 0-5 
year-olds is the best cut-off for discontinuing MDA is unknown. It has been pointed out by 
others that studies to ascertain a threshold or thresholds below which trachoma infections do 
not persist and will then disappear on their own (i.e. the existence of an ‘Allee effect’) will be 
very difficult to conduct against the background of worldwide downward secular trends in 
trachoma prevalence [24]. However, one interpretation of the PRET data would be that The 
Gambia reached such a point before the PRET study started, when the application of tests for 
infection would have shown a baseline infection prevalence of 0.8%. We suggest that tests 
for Ct infection will be needed to confirm whether, or, more likely, when a country, region or 
district is ready to discontinue MDA. We show that the application of such tests with 
appropriate sampling schemes and decision rules will save money relative to initiating or 
continuing MDA, even with the current costs of NAATs.       
 
Our study had a number of limitations which may affect the results. We did not  include the 
opportunity cost of people coming to be treated and/or examined in relation to  what they 
would otherwise have been doing, what this represented in monetary terms, and how long 
each adult spent with the team. The NEHP workers administering treatment were taken away 
from their usual tasks, also incurring societal costs. Our total cost estimates are therefore 
likely to under-estimate the total societal cost. By not including the opportunity cost, we may 
have masked cost differences between the strategies, depending on the amount of time an 
adult spent when attending and accompanying children for treatment distribution, compared 
with accompanying children for examination. Studies comparing different trachoma 
treatment strategies have noted that patient (opportunity) cost is a major cost in mass 
azithromycin treatment with donated drug [19,25]. We probably under-estimated the cost of 
the extra treatment day in the enhanced treatment strategy as, per person, the teams would 
have spent longer per person treated trying to find the few remaining individuals needing 
treatment than treating people when arriving in an EA for the first day. As the extra day had 
no impact on outcome, this concern is minor. Finally, however, our data are taken from a 
research project. Although we have made substantial efforts to separate out and remove 
research costs, the census, treatment and examination activities may have been organised and 
conducted differently if entirely planned and run by the programme. Programmes may elect 
for example to combine census and treatment activities. Thus, absolute costs would probably 
vary with a different project organisation (and be different in another low prevalence 
country), but we suggest that the relative cost differences we highlight between three annual 
MDAs and a stopping rule based on testing for infection would be less affected.  
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If azithromycin were purchased rather than donated, the cost of treatment was 6.7 times 
greater with azithromycin constituting over 80% of the total cost. This is much more than the 
costs of testing and, without the donation programme it would be cheaper to test first if there 
were even a minority of communities with low levels of infection as purchasing azithromycin 
is prohibitively expensive [19,25,26,27]. This underlines the importance of the donation to 
national eye health programmes in their quest to eliminate trachoma as a public health 
problem.  
 
 
Conclusion: 
We have shown that the strategy of three annual rounds of mass azithromycin treatment of a 
sub-district are more expensive than examining and testing ocular swabs from a sample of 
EAs, if, as in the PRET study treatment can then be discontinued based on the results after 
one round. Therefore, in low prevalence settings, it could be both cost-saving and cost-
effective to implement a stopping rule strategy. 
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Figure legends 
 
Figure 1. Illustrating the strategies involving MDA and testing whose costs are compared. In 
red is the base strategy of three rounds of MDA in the study area. In blue is strategy 1, testing 
all EAs after one round of treatment. In green, strategy 2, testing 8 EAs after one round of 
treatment. In yellow, strategy 3, discontinuing treatment based on examination after one 
round of treatment. In purple, strategy 4 of not starting MDA at all based on prior testing of 8 
EAs 
 
 
Figure 2. Pie charts illustrating relative component costs for treatment, examination and 
testing 
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Figure 3.Illustrating how kit cost of testing affects cost of testing each EA after one round of 
MDA compared to continuing for 3 rounds. 
 
 
 
Table 1. Prevalence of TF and ocular C. trachomatis infection in PRET by allocation 
 3 annual MDAs Stopping rule ( 
MDA at baseline 
only) 
Standard coverage 
(one  treatment 
visit) 
Enhanced coverage 
(extra treatment  
visit) 
Time 
point 
TF (%) Ct (%) TF (%) Ct (%) TF (%) Ct (%) TF (%) Ct (%) 
Baseline 6.5 0.8 6.1 0.6 5.8 0.4 6.8 1.1 
6 months  2.4 0.1 2.4 0  2.2 0  2.5 0.1 
36 months  2.6 0.6 2.9 0.4 2.4 0.6 3.1 0.4 
 
 
Table 2. Census costs by item 
Item  Cost(USD) 
Training(fixed): 
Salary   11.63  
Trainers  and supervision       74.54  
Per diem       22.62  
Total training cost  108.79  
Cost per EA: 
Personnel 
Salary  5.71 
Per diem  7.54  
Materials 
Stationery (Pens, Clipboard):    1.89  
Paper   0.50  
Plastic wallet   0.56  
Phone credit   0.38 
Transport 
Motorcycle depreciation   1.52  
Fuel       4.33  
Data entry  3.08  
Supervision  
Salary   37.37  
Vehicle depreciation   16.84  
Fuel    23.52  
Total per EA cost  103.24  
Cost for 102 EAs  10530.48  
Total census cost for study area  10639.27  
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Table 3. Costs of MDA rounds 
  
EAs made up of smaller 
settlements (M-multiple) 
  
EAs made up of one 
settlement (S-single) 
  
EAs part of a large 
settlement (G-segment) 
  
Weighted average across 48 
study EAs: 25M 7S 16G   
  
Weighted average across 
102 EAs in the study area:  
31M 11S 60G 
  
                               
Costing category Standard   Enhanced   Standard   Enhanced   Standard   Enhanced   Standard  Enhanced  Standard   Enhanced   
Personnel  109.4 168.3 94.7 106.4 136.4 204.3 116.26 171.27 123.70 182.80 
Fuel 6.3 10.2 3.7 4.1 12 15.7 7.82 11.14 9.37 12.78 
Equipment  9.3 14.8 8.3 9.3 10.5 15.8 9.55 14.33 9.90 14.80 
Supervision 77.8 77.8 77.8 77.8 77.8 77.8 77.8 77.8 77.8 77.8 
Data entry 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 
Tetracycline 2.8 3.5 1.7 2.2 4.8 5.9 3.31 4.11 2.98 4.77 
Average total 
cost/EA, excluding 
azithromycin 208.7 277.7 189.3 202.9 244.6 322.6 217.84 281.76 227.73 296.05 
Azithromycin 1658.6 1874.3 945.5 1195.1 1088.6 1192.9 1364.61 1548.12 1246.40 1400.23 
Average total 
cost/EA, including 
azithromycin 1867.3 2152 1134.8 1398 1333.2 1515.5 1582.44 1829.88 1474.13 1696.27 
15 
 
Table 4. Estimated examination and testing cost per EA in the study EAs and across the study ar
  
  
          
Costing 
category 
Average cost per 
EA (USD) 
      
EA type: Multiple(M) Single(S) Segment(G) 
48 study EAs adju
EA type(16M 7S
Field personnel 58 121.9 78.7 74.22 
Field 
consumables 58.4 61.1 58.2 58.73 
Field equipment 9.7 18.1 12.7 11.93 
Field 
supervision 77.8 77.8 77.8 77.8 
Fuel 16.7 12.8 17.1 16.26 
Lab personnel 20.6 21.5 20.5 20.70 
Lab 
consumables 43.8 45.8 43.6 44.03 
Lab kit 
(Amplicor) 479 500.6 477 481.48 
Lab equipment 6.6 6.9 6.5 6.61 
Lab supervision 1.8 1.9 1.8 1.81 
Data entry 1.5 1.5 1.5 1.5 
Estimated total 
cost/EA 773.9 869.9 795.4 795.07 
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